Recursion lays out $300M+ goal in IPO terms; Evotec and Bristol Myers team up to spin out German research
Recursion is nearly ready to make its public debut, and the biotech set out what the potential raise might look like Monday.
Recursion set its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
